Late complications after leukemia therapy

Hudson, Melissa M.

doi:10.1017/cbo9780511471001.031

Cited by 4 publications

(4 citation statements)

References 260 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demyelination and radiation necrosis of white matter are well documented following CNS treatment [Burger and Boyko, 1991]. White matter injury and leukoencephalopathy have been associated with ITC alone, especially with methotrexate [Hudson, 1999]. Thus, white matter injury is perhaps the principal factor in irradiation and chemotherapy-related CNS damage, even though these insults likely impact on all brain tissues.…”

Section: Treatment Induced Neuropathology Of Neurocognitive Deficitsmentioning

confidence: 99%

Neurocognitive effects of treatment for childhood cancer

Butler

Haser

2006

Ment. Retard. Dev. Disabil. Res. Rev.

170

137

View full text Add to dashboard Cite

We review research on the neuropsychological effects that central nervous system (CNS) cancer treatments have on the cognitive abilities of children and adolescents. The authors focus on the two most common malignancies of childhood: leukemias and brain tumors. The literature review is structured so as to separate out earlier studies, generally those published prior to 1995, as opposed to manuscripts that have been published within the past decade. This is an important distinction for both leukemia and brain tumors. Earlier studies were ground breaking in that they began to map out what could be expected in terms of intelligence and academic problems in survivors of pediatric malignancies. Survivorship in this population has and continues to markedly increase and this is largely due to changes in treatment protocols. Research on neurocognitive effects of disease and treatment in pediatric oncology has become increasingly sophisticated, and this literature review not only reflects this trend, but highlights the growing collaboration between neuropsychology, cognitive neuroscience, and neuro-imaging. Thus, our goal was to provide a historical foundation, lead the reader towards the progression of research methodology up to the current state of the art, and perhaps most importantly, discuss future directions. These directions are especially relevant to the concepts of remediation and treatment of cognitive problems, and this is emphasized at the conclusion of the review.

show abstract

Section: Treatment Induced Neuropathology Of Neurocognitive Deficitsmentioning

confidence: 99%

Neurocognitive effects of treatment for childhood cancer

Butler

Haser

2006

Ment. Retard. Dev. Disabil. Res. Rev.

170

137

View full text Add to dashboard Cite

show abstract

“…The subject of late effects among children treated for cancer has been the topic of numerous reviews (Boulad et al , 1998; Marina, 1997; Hudson, 1999; Bhatia et al, 2002a; Dreyer et al, 2002). To varying degrees, it has been shown that disease‐ or treatment‐specific subgroups of long‐term survivors are at risk of developing adverse outcomes including early death, second neoplasms, organ dysfunction (e.g.…”

Section: Introductionmentioning

confidence: 99%

Late‐effects among survivors of leukaemia and lymphoma during childhood and adolescence

Robison

Bhatia

2003

Br J Haematol

View full text Add to dashboard Cite

With improvements in survival rates for children and adolescents diagnosed with leukaemia or lymphoma, issues relating to late treatment-related sequelae have increased in importance. Reviewed are selected late adverse outcomes, including second malignancies, cardiotoxicity, endocrinological effects, impact on neurocognitive ⁄ neuropsychological status, late mortality and implications of stem cell transplantation. While there has been considerable research on the late outcomes among survivors of acute lymphoblastic leukaemia and Hodgkin's disease, future research must be directed towards identification of risks associated with more recent treatment regimens, as well as the very lateoccurring outcomes resulting from treatment protocols utilized three or more decades ago. As treatment-and patient-related factors impact the subsequent risk of lateoccurring adverse outcomes, clear delineation of those leukaemia and lymphoma survivors who are at high risk of specific adverse outcomes is essential for the rational design of follow-up guidelines, prevention and intervention strategies.

show abstract

“…The prognosis of childhood cancer has markedly improved since the 1970s, mainly due to improvements in multidisciplinary therapy, including neoadjuvant chemotherapy, radiation therapy and surgical techniques. However, with the increase in the number of long-term survivors, the prevalence of latent treatment-related adverse effects, such as secondary malignancy, has increased (15).…”

Section: Discussionmentioning

confidence: 99%

Secondary osteosarcoma in patients previously treated for childhood cancer: Three case reports

et al. 2018

View full text Add to dashboard Cite

The prognosis of childhood cancers has improved markedly, and the proportion of long-term survivors has increased in recent years. However, with the increase in the number of long-term survivors, the development of latent treatment-related adverse effects, such as secondary malignancies, has generated new problems. Secondary cancer is defined as a histologically distinct malignancy that develops at least 2 months after the completion of treatment for primary cancer. Genetic factors and acquired conditions associated with treatment modalities are possible causes of secondary malignancy development. Genetic factors include the presence of Li-Fraumeni syndrome (LFS) and retinoblastoma. In terms of acquired factors, radiation and chemotherapy have been reported to be the most strongly associated with secondary malignancy development. The use of alkylating agents and topoisomerase II inhibitors for the treatment of childhood cancer increases the subsequent risk of secondary tumors. We herein investigated three cases of secondary osteosarcoma several years after treatment for primary cancer. In the three patients, the familial history did not appear to fit the clinical diagnostic criteria of LFS or retinoblastoma. The patients had not received previous radiation therapy to the anatomical site of the secondary cancer. However, high dosages of alkylating agents and topoisomerase II inhibitors had been administered for the treatment of primary cancer. The exact link between chemotherapy and secondary cancer remains elusive, but the possibility of an association should be considered. Following the development of multidisciplinary therapies, long-term follow-up and monitoring of latent adverse effects may be necessary for childhood cancer survivors.

show abstract

Late complications after leukemia therapy

Cited by 4 publications

References 260 publications

Neurocognitive effects of treatment for childhood cancer

Neurocognitive effects of treatment for childhood cancer

Late‐effects among survivors of leukaemia and lymphoma during childhood and adolescence

Secondary osteosarcoma in patients previously treated for childhood cancer: Three case reports

Contact Info

Product

Resources

About